Bristol Myers Squibb Company (NYSE:BMY) Stock Position Lifted by National Pension Service

Key Points

• The National Pension Service increased its stake in Bristol Myers Squibb by 5.0% in Q1, owning 4.9 million shares valued at approximately $299 million.
• Bristol Myers Squibb reported an EPS of $1.46 for the last quarter, exceeding analysts' expectations of $1.07, alongside a revenue of $12.27 billion.
• The company declared a quarterly dividend of $0.62 per share, representing a 5.3% annual yield, with a payout ratio of 100%.

National Pension Service raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 5.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,903,014 shares of the biopharmaceutical company's stock after purchasing an additional 234,190 shares during the period. National Pension Service owned 0.24% of Bristol Myers Squibb worth $299,035,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BMY. Ameriprise Financial Inc. boosted its stake in Bristol Myers Squibb by 59.9% during the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of Bristol Myers Squibb by 701.2% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock worth $705,309,000 after acquiring an additional 10,913,708 shares during the period. Nuveen LLC acquired a new stake in shares of Bristol Myers Squibb in the 1st quarter worth approximately $624,369,000. Northern Trust Corp lifted its stake in shares of Bristol Myers Squibb by 16.2% in the 4th quarter. Northern Trust Corp now owns 24,658,360 shares of the biopharmaceutical company's stock worth $1,394,677,000 after acquiring an additional 3,431,248 shares during the period. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of Bristol Myers Squibb by 72.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 7,769,227 shares of the biopharmaceutical company's stock worth $439,427,000 after acquiring an additional 3,275,061 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Trading Up 1.3%

Shares of BMY stock traded up $0.64 during trading hours on Friday, reaching $48.45. 11,206,898 shares of the stock traded hands, compared to its average volume of 12,717,643. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The business has a fifty day moving average price of $47.23 and a 200 day moving average price of $51.50. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The firm has a market capitalization of $98.62 billion, a PE ratio of 19.54, a PEG ratio of 2.44 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same quarter in the previous year, the business earned $2.07 earnings per share. The firm's revenue was up .6% compared to the same quarter last year. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were issued a dividend of $0.62 per share. The ex-dividend date was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.1%. Bristol Myers Squibb's payout ratio is currently 100.00%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on BMY shares. Citigroup reduced their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a research note on Friday, August 1st. Piper Sandler started coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target for the company. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Daiwa America lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $56.38.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.